OREANDA-NEWS. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specialising in the treatment of wounds and skin defects, today announced that it has appointed a distributor to sell its devices into the German, Austrian and Swiss markets.

MSM Medical sells advanced wound care products into the key German-speaking territories through its eight sales staff located in offices in Gomadingen, Vienna and Zurich. Avita Medical said it believed its regenerative medicine devices, which enable a clinician to rapidly create Regenerative Epithelial Suspension (RES™) by using a small sample of the patient's skin, fitted well within MSM Medical's product portfolio. The agreement, which came into commercial effect Feb. 10 will cover exclusive distribution across Avita's full product range in Germany, Austria and Switzerland.

Avita Medical is rolling out its CE-marked product range across Europe by appointing distributors with longstanding relationships in the sector. The strategy is aimed at giving Avita a deeper reach and faster penetration into the burns, wound care and aesthetic surgery markets.

"When choosing a distributor, we must have comfort that they are able to effectively demonstrate to medical professionals how ReCell® can be deployed to benefit patients," said Adam Kelliher, UK-based CEO of Avita Medical. "We quickly saw that MSM Medical have the appropriate expertise, and well-proven capabilities in supporting the sales of medical device products in the German-language wound care market."

As with other distributor markets, Avita will support MSM Medical with publicity and clinical platforms, and a focused training programme for clinicians deploying the single-use device. The company recently announced appointments of distributors in the UK, France, Japan and South Korea, and said it has commenced commercial discussions with parties in other key territories.